CALMARE® Therapy Treatment
Project Number:
Marineo-01-07
Patent Numbers:
US patent pending
FDA 510(k) clearance for US sales
European Union Medical Device CE approved as an electronic-analgesic apparatus
FDA 510(k) clearance for US sales
European Union Medical Device CE approved as an electronic-analgesic apparatus
Inventor:
The technology is from the research of Professor Giuseppe Marineo, a researcher and bioengineer, and the founder and manager of Delta Research & Development. Delta R&D, formed in May 1998, is a Medical Bioengineering Research Centre affiliated with Tor Vergata University of Rome in Italy.
Description:
The pain therapy technology is a non-invasive method for rapid treatment of high-intensity oncologic, neuropathic, and drug-resistant pain through a biophysical rather than a biochemical manner. The method incorporates electromedical equipment for electronic nerve stimulation, and uses the nerve fiber as a passive means to convey a message of normality to the central nervous system (CNS) by a procedure defined as scrambling or tricking of information, which then enables the CNS to modify the reflex adaptive responses - referred to as TEMPR - Transcutaneous Electrical Modulation Pain Reprocessor. It has been successfully used on over 3,000 patients in Europe.
Advantages:
The non-invasive MC-5A, using Scrambler technology, is a multiprocessor apparatus able to simultaneously treat multiple pain areas in the individual. The patient experiences longer "no pain" periods after each successive treatment.
Applications:
The global pain management market is estimated to reach $40 billion by 2010. Potential market opportunities include hospitals, nursing homes and hospices, cancer treatment centers, and pain management centers.
CTT has granted exclusive distribution rights for the MC-5A to Excel Life Sciences, Inc. for India, to GEOMC Co., Ltd. for Korea, to AG Healthcare for Malaysia, and to Biogene Pharma Limited for Bangladesh. In addition, country-exclusive distribution rights have been granted to Life Epistéme srl for each of 31 countries throughout Europe, Asia, Africa, the Middle East, South America and Oceania. The agreements, covering 35 countries around the world, account for over 48% of the world's population.
CTT has granted exclusive distribution rights for the MC-5A to Excel Life Sciences, Inc. for India, to GEOMC Co., Ltd. for Korea, to AG Healthcare for Malaysia, and to Biogene Pharma Limited for Bangladesh. In addition, country-exclusive distribution rights have been granted to Life Epistéme srl for each of 31 countries throughout Europe, Asia, Africa, the Middle East, South America and Oceania. The agreements, covering 35 countries around the world, account for over 48% of the world's population.
For more information please contact:
Aris D. Despo
Executive Vice President, Business Development
This email address is protected, Javascript must be enabled to view it
Tel: 704.519.5443
Device: MC-5A
Friday, March 12th 2010
Terms of Service | Privacy Statement | 